To date zidovudine is the only antiretroviral agent approved by the FDA as clinically effective. However, zidovudine has serious toxicities, including neutropenia and anemia; in some patients dosage reduction or cessation of therapy may be necessary. Because treatment with zidovudine does not cure HIV infection, numerous studies are under way with other anti-HIV agents. Ultimately, combinations of agents probably will be used to suppress or eradicate HIV. While the search for more efficacious and less toxic treatments continues, the development of zidovudine in such a short time provides hope that progress toward a cure will be made rapidly. Published in Clinical pharmacy (1987)

The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART To evaluate the safety and efficacy of arsenic trioxide combined with cART in eliminating latent HIV-1 reservoir, providing potential strategies for AIDS functional cure. Although combined antiretroviral therapy (cART) could control human immunodeficiency virus type 1 (HIV-1) infection, the persistence of HIV-1 viral reservoir make it extremely difficult to achieving cure of AIDS. The shock and kill strategy has been extensively practiced. The latency reversing agents (LRAs) could reactivate latent HIV-1 and then the reactivated virus could be eradicated. However, no appropriate activator has been found nor manufactured. Our previous work found that the arsenic trioxide, clinically approved for treating acute promyelocytic leukemia,could efficiently reactivate latent provirus in CD4+T cells from HIV-1 patients and Simian immunodeficiency virus (SIV)-infected macaques, without significant systemic T cell activation and inflammatory responses.

To identify the main types of HIV cure-related strategies and examine possible risks (and benefits) associated with participating in HIV cure-related research studies.We undertook a scoping review to first map out the landscape of HIV cure-related research and then examined the risks and potential benefits associated with participating in HIV cure research. Given the early stage of many HIV cure-related studies, we used proxy literatures from non-cure HIV research and cancer research in order to anticipate possible motivators and deterrents of participation in HIV cure-related studies.We discussed four main categories of HIV cure-related research: (1) early antiretroviral treatment (ART); (2) latency-reversing agents (LRAs); (3) therapeutic vaccinations and immune-based therapies (IBT); and (4) stem-cell transplantation and gene therapy. At this juncture, these categories of HIV cure-related research have substantial individual risks and negligible individual and clinical benefits. Non-cure HIV research (including HIV prevention and treatment) and cancer research have empirical similarities (and differences) to HIV cure research and may provide an opportunity to anticipate ethical and logistical challenges associated with HIV cure-related research participation and decision-making. Learning from the cancer field, a strong foundation of patient-participant and clinician-researcher trust will need to be established to facilitate recruitment of participants into HIV cure-related

Treating HIV | HIV | CDC Skip directly to site content Skip directly to search An official website of the United States government Here's how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. April 12, 2024 Treating HIV Key points There is no cure for HIV, but HIV treatment can reduce the amount of HIV in your body. There are two types of HIV treatment: pills and shots. Most people can get HIV under control within six months. HIV treatment prevents transmission to others and helps you stay healthy. Overview HIV treatment (antiretroviral therapy or ART) involves taking medicine prescribed by a health care provider. When taken as prescribed, HIV medicine can make the amount of virus in your body ( viral load ) so low that a test can't detect it ( undetectable viral load ). View Larger Download Having an undetectable viral load also prevents transmission to others. Start HIV treatment as soon as possible after diagnosis All people with HIV should take HIV treatment, no matter how long they've had HIV or how healthy they are. If you delay treatment, HIV will continue to harm your immune system and increase your chances of transmitting HIV to others, getting sick, and developing AIDS. Low Resolution Video Treatment types There are two types of HIV treatment: pills and shots. Pills are recommended for people just starting HIV treatment. There are many FDA-approved single pill and combination medicines available. HIV treatment shots are long-acting injections given once a month or once every other month, depending on your treatment plan. Shots may be right for you if you are an adult with HIV who has had an undetectable viral load (or has achieved viral suppression) for at least three months, has no history of treatment failure, and has no

Despite significant advances in antiretroviral therapy, the need for a cure for HIV persists because of factors such as long-term antiretroviral therapy-related comorbidities, disease stigma, and inequities in access to care. Most cure efforts focus on inducing durable HIV remission (antiretroviral therapy-free viral control) either by augmenting immune function or reducing the HIV reservoir. In this review, we highlight immune-based cure interventions currently under investigation with a particular focus on those that have demonstrated the ability to induce durable HIV remission after analytic treatment interruption, here termed "post-intervention control". While current cure interventions are generally complex, expensive, and not easily scalable, they provide critical "proof of principle" that a cure for HIV is possible. Continuing to make studies of HIV cure a funding priority is important, we believe, as continued optimization of cure interventions should eventually lead to a cure that is simple, safe, effective, affordable, and scalable. In addition, we highlight critical features in clinical trial design and pharmacokinetics/pharmacodynamics that should be considered prior to clinical trial implementation.

A Prospective Cohort for ex Vivo Cure Studies With Chronic HIV Infected Patients in the Netherlands A prospective non-interventional cohort study at Erasmus MC of adult chronic HIV infected patients of ≥18 years of age who initiate antiretroviral therapy in routine care. HIV cannot be cured with the current treatment armamentarium. A reservoir of latently HIV infected long lived CD4+T-cells is present in patients with HIV that are not affected by antiretroviral therapy. The evolution of this reservoir after therapy initiation is ill understood, as are the potential strategies to eradicate this reservoir. This study aims to anticipate on future HIV cure strategies by building a cohort to study ex vivo the reservoirs of HIV patients, the obstacles to cure HIV, and new therapeutic compounds and strategies. Main study parameters/endpoints: 1. Change in viral reservoir size after antiretroviral treatment initiation. 2. Evolution of phenotypical and functional aspects of the anti-HIV host immune responses. 3. Ex vivo activity of established and novel HIV latency reversing agents. 4. Variance in HIV reservoir and host immunity between HIV subtypes and clinical variables.

Although current antiretroviral therapy (ART) is highly effective at controlling HIV-1 replication, it does not eradicate or cure the infection. HIV-1 persists quiescently in cellular reservoirs, not detected by the immune system due to the lack of active viral replication; these reservoirs represent the major obstacle for cure approaches. Reversal of HIV-1 latency and induction of virus expression by a variety of interventions may render infected cells susceptible to immune recognition and active clearance. Strategies to boost immune responses via vaccination, immunomodulation, or gene therapy are being evaluated with the aim of achieving HIV-1 control without antiretroviral therapy, if not viral eradication.

Latently infected resting CD4+ T cells represent the principal barrier to HIV eradication. Their immunological quiescence renders them invisible to combination antiretroviral therapy (cART) and host immune surveillance, sustaining a reservoir that mandates lifelong treatment. The 'shock and kill' strategy seeks to reverse this latency using pharmacological latency-reversing agents (LRAs) so that immune effectors and cART can eliminate reactivated cells. In this narrative, structured review, we examine histone deacetylase inhibitors (HDACis) as LRAs from a medicinal chemistry perspective. The review places particular emphasis on structure-activity relationship (SAR), isoform selectivity, and the mechanistic basis of differential clinical performance, synthesizing evidence from preclinical, ex vivo, and clinical studies published between 2010 and 2026. Four structural classes of HDACis-hydroxamic acids, benzamides, cyclic depsipeptides, and short-chain fatty acids-differ substantially in isoform selectivity, potency, pharmacokinetics, and tolerability. No single agent has achieved statistically significant reservoir reduction in clinical trials, highlighting the apparent inadequacy of the 'shock' phase alone and suggesting a need for complementary 'kill' strategies. Rational design of HDACis informed by isoform-selective SAR, combined with emerging combination LRA strategies and immunological 'kill' components, represents a promising direction toward a functional HIV cure, though substantial translational hurdles remain.

Proclamation 5892 ← Ronald Reagan's Presidential Proclamations Proclamation 5892—National AIDS Awareness and Prevention Month, 1988 by Ronald Reagan → sister projects : Wikipedia article , Wikidata item Delivered on 28 October 1988. 62597 Proclamation 5892—National AIDS Awareness and Prevention Month, 1988 Ronald Reagan By the President of the United States of America A Proclamation Nearly 75,000 Americans have been diagnosed as having the fatal disease AIDS, and more than 41,000 have already died from it. The Public Health Service estimates that an additional one to one-and-a-half million Americans have been infected by the Human Immunodeficiency Virus (HIV), which causes AIDS. Most of the infected individuals now show no symptoms, but it is likely that over the next few years they will develop AIDS or AIDS-related illnesses. Extensive efforts by Government and the private sector are underway in the fight against AIDS and HIV infection, and great strides have been made. In the 7 years since the first reports of AIDS cases, the virus has been identified; the ways in which it is spread have been pinpointed; an AIDS antibody screening test has been developed and is being used to protect blood supplies; the first steps toward development of a protective vaccine have been taken; and promising drugs to fight the HIV and its manifestations are being synthesized and tested. Nevertheless, today we have neither a cure for AIDS nor a vaccine against HIV infection. For this reason, it i

Proclamation 6694 ← Bill Clinton's Presidential Proclamations Proclamation 6694 - Pediatric and Adolescent AIDS Awareness Week, 1994 by Bill Clinton → sister projects : Wikipedia article , Wikidata item Delivered on 25 May 1994. 60399 Proclamation 6694 - Pediatric and Adolescent AIDS Awareness Week, 1994 Bill Clinton By the President of the United States of America A Proclamation Ten thousand children in the United States today are living with the human immunodeficiency virus (HIV). Ten million children worldwide will become infected with HIV before the millennium. Over 5,000 cases of pediatric AIDS and 1,500 cases of AIDS in adolescents ages 13 through 19 have been reported in this country alone. The tragedy is magnified for our youth, as the epidemic reaches far beyond those actually infected-it will leave up to 125,000 children and teenagers orphaned in this country by the end of this decade. By the year 2000, AIDS will be one of the five leading causes of death among American children ages one to four. It is agonizing to watch our young suffer and die. It is all the more painful because we have been frustrated thus far in our efforts to find a cure. But we must not give up hope nor stand by idly. With hard work, we will find that cure. Moreover, HIV and AIDS are preventable. Americans can stop AIDS with targeted, linguistically specific, and culturally based prevention education for people in all age groups. If we are to overcome the HIV epidemic, communities must address

as for basic research for a vaccine and a cure. Local and international nongovernmental organizations … are painful dilemmas. In countries where HIV has spread widely, the epidemic will greatly … AIDS. Starting from the view that government has a mandate to advance economic well-being and